Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acasti Pharma
(NQ:
ACST
)
0.4311
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Mar 28, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acasti Pharma
< Previous
1
2
3
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 22, 2023
The biggest pre-market stock movers are making waves on Wednesday with huge gainers and losers worth watching this morning!
Via
InvestorPlace
Acasti Pharma Reports Third Quarter 2023 Operational Results
February 14, 2023
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
January 25, 2023
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Earnings Scheduled For February 14, 2023
February 14, 2023
Companies Reporting Before The Bell • WESCO International (NYSE:WCC) is projected to report quarterly earnings at $3.79 per share on revenue of $5.37 billion.
Via
Benzinga
Acasti Pharma's Earnings Outlook
February 13, 2023
Via
Benzinga
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
January 24, 2023
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast
January 17, 2023
Phoenix, Arizona--(Newsfile Corp. - January 17, 2023) - The Stock Day Podcast welcomed Acasti Pharma, Inc. (NASDAQ: ACST), a late-stage...
Via
Newsfile
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
January 13, 2023
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
January 06, 2023
Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
January 06, 2023
The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
January 05, 2023
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
December 28, 2022
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
December 23, 2022
Gainers
Via
Benzinga
Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket
December 23, 2022
Gainers Expion360 Inc. (NASDAQ: XPON) shares rose 152% to $2.47 in pre-market trading. Expion360 been selected as the exclusive supplier of high-energy lithium ion batteries for an overland trailer...
Via
Benzinga
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
December 22, 2022
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
December 19, 2022
Via
Benzinga
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
December 20, 2022
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
November 14, 2022
Monday saw 33 companies set new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
December 15, 2022
Via
Benzinga
Acasti Pharma Reports Second Quarter 2023 Operational Results
November 14, 2022
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Stocks That Hit 52-Week Lows On Friday
November 11, 2022
On Friday, 63 stocks hit new 52-week lows.
Via
Benzinga
Acasti Pharma to Present at Q4 Investor Summit
November 09, 2022
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022
November 07, 2022
Call to be held on Monday, November 14th at 1:00 PM Eastern Time
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Acasti Pharma Inc. (NASDAQ:ACST) (TSX.V:ACST) Featured in Coverage of Investor Summit Group’s Q4 Event
November 04, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Acasti Announces Court Dismissal of Stockholder Litigation
September 30, 2022
From
Acasti Pharma, Inc.
Via
Globe NewsWire
121 Stocks That Hit Their 52-Week Low
October 14, 2022
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.
Via
Benzinga
Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
September 29, 2022
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast
September 21, 2022
Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"),...
Via
Newsfile
Exposures
Product Safety
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
July 27, 2022
From
Acasti Pharma, Inc.
Via
Globe NewsWire
Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day Podcast
July 07, 2022
Phoenix, Arizona--(Newsfile Corp. - July 7, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"),...
Via
Newsfile
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.